Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

998 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The practice of intraoperative blood salvage and autotransfusion (IBSA) during deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) can potentially reduce the need for allogeneic blood transfusion. However, implementing IBSA remains debatable due to concerns about its possible detrimental effects on oncologic recurrence. Hence, a nationwide multi-center study was conducted to investigate further the association between IBSA and post-transplant HCC recurrence, including a stratified subgroup analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AutoTransfusion Versus TRAnsfusion in Cancer Surgery

NCT05452538

Hemorrhage Cancer Surgery Transfusion

COMPLETED

Recurrence of Hereditary Hemorrhagic Telangiectasia (HHT) After Liver Transplantation

NCT03942315

Hereditary Haemorrhagic Telangiectasia Liver Transplant

COMPLETED

Blood Salvage in Orthotopic Liver Transplantation With HCC

NCT05612477

Hepatocellular Carcinoma Surgery

ACTIVE_NOT_RECRUITING NA

Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant

NCT04265157

Liver Transplant

UNKNOWN

Blood Salvage From Liver Donors: a Feasibility Pilot Study

NCT05835882

Liver Transplantation Erythrocyte Transfusion

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplant; Complications

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intraoperative blood salvage and autotransfusion (IBSA) group

The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria included: patients under 18 years of age, presence of extrahepatic metastasis, combined kidney transplantation, reduced-size or split liver transplantation, re-transplantation, and missing data on analyzed variables. The remaining recipients were 349 in IBSA group who received salvaged blood autotransfusion during the LT.

No interventions assigned to this group

non-intraoperative blood salvage and autotransfusion (non-IBSA) group

The study included patients who underwent adult-to-adult DDLT for HCC in China between January 2015 and December 2020. Exclusion criteria was as mentioned ahead. Recipients who did not receive salvaged blood autotransfusion during the LT were enrolled in non-IBSA group.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* adult-to-adult deceased donor liver transplantation for hepatocellular carcinoma

Exclusion Criteria

* patients under 18 years of age
* presence of extrahepatic metastasis
* combined kidney transplantation
* reduced-size or split liver transplantation
* re-transplantation

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No